Jordyn Silverstein, MD, MSc, discusses updated data with abemaciclib plus hormonal therapy in ER-positive endometrial cancer and low-grade serous ovarian cancer.
Jordyn Silverstein, MD
Advertisement
Jordyn Silverstein, MD, is a hematology/oncology fellow at UCLA Health.
Articles by Jordyn Silverstein, MD
Jordyn Silverstein, MD, discusses the efficacy of abemaciclib plus hormonal therapy in recurrent ovarian cancer or endometroid endometrial cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026
5